Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPLEMENT A+B: Ofatumumab + Bendamustine in Indolent B-cell NHL
NCT01077518Phase 3Terminated
- Sponsor
- Novartis
- Start
- Aug 2010
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of ofatumumab in B-cell non-Hodgkin lymphoma, sponsored by Novartis. Started Aug 2010; status: terminated.
02
Drugs
ofatumumab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT01077518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01077518.